Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Meredith A. McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, discusses the rationale behind targeting the oncogenic transcription factor C/EBPβ in patients with advanced and metastatic solid tumors, including melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.